Erectile Response of Intracavernous Injection of New Triple Agents, Chlorpromazine, Papaverine, and Alprostadil.
- Author:
Yong Seong LEE
1
;
Sae Chul KIM
Author Information
1. Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea. saeckim@unitel.co.kr
- Publication Type:Original Article
- Keywords:
Erectile dysfunction;
Phentolamine;
Chlorpromazine
- MeSH:
Alprostadil*;
Chlorpromazine*;
Erectile Dysfunction;
Humans;
Male;
Papaverine*;
Phentolamine
- From:Korean Journal of Urology
2003;44(11):1121-1123
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was aimed to compare the erectile response when phentolamine of intracavernous trimix(papaverine, phentolamine, alprostadil) was replaced with chlorpromazine. MATERIALS AND METHODS: A total of 65 patients with erectile dysfunction(63.3+/-9.19 years of age) who had already used intracavernous injection with trimix(4.5+/-2.12 years) were recruited for this study. The erection quality and adverse reactions of chlorpromazine solution were compared with those of trimix. RESULTS: Among 65 patients, the erection quality of the intracavernous chlorpromazine solution compared to that of trimix was worse in 26 patients(40%), better in 8(12.3%) and similar in 31(47.7%) when injected at the clinic. Among 45 patients who used the chlorpromazine solution for intracavernous self-injection at home for more than 3 months, however, the erection quality was worse in 13(28.9%), better in 8(17.8%) and similar in 24(53.3%). Intracavernous chlorpromazine solution-either injected at the clinic or self-injected-showed no significant adverse reaction. CONCLUSIONS: Chlorpromazine could be a safe and effective substitude of phentolamine of trimix.
